Unexpected margin drop in EMEA, but Q2 revenues were up +9% (+15% at cc) to US$4,199m although the gross profit margin weakened from 31.6% to 30.9%. EBITDA was broadly unchanged at US$728m and net profit attributable to shareholders was up +3% to US$241m. Operating CF dropped -14% to US$385 burdened by a higher NWC outflow, whereas investing CF moved from US$-515m to US$-269m helped by lower acquisition costs. FCF after investing activities swung from US$-66m to US$116m. Management confirmed
30 Jul 2015
EMEA becoming a challenge in US$ terms
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
EMEA becoming a challenge in US$ terms
Fresenius Medical Care AG (FME:WBO) | 0 0 0.7% | Mkt Cap: 26,769m
- Published:
30 Jul 2015 -
Author:
Martin Schnee -
Pages:
2
Unexpected margin drop in EMEA, but Q2 revenues were up +9% (+15% at cc) to US$4,199m although the gross profit margin weakened from 31.6% to 30.9%. EBITDA was broadly unchanged at US$728m and net profit attributable to shareholders was up +3% to US$241m. Operating CF dropped -14% to US$385 burdened by a higher NWC outflow, whereas investing CF moved from US$-515m to US$-269m helped by lower acquisition costs. FCF after investing activities swung from US$-66m to US$116m. Management confirmed